As of Friday close, Verve Therapeutics Inc.’s (NASDAQ:VERV) stock was down -$0.53, moving down -3.64 percent to $14.04. The average number of shares traded per day over the past five days has been 678,640 shares. 1 time new highs have been achieved over the past 5 days, with a -$3.94 fall in that time frame. In the last twenty days, the average volume was 577,915, while in the previous 50 days, it was 640,784.
Since last month, VERV stock retreated -29.20%. Shares of the company fell to $14.02 on 08/18/23, the lowest level in the past month. A 52-week high of $43.00 was reached on 02/02/23 after having rallying from a 52-week low of $13.01. Since the beginning of this year, VERV’s stock price has dropped by -27.44% or -$5.31, and marked a new high 10 times. However, the stock has declined by -67.35% since its 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
VERV stock investors should be aware that Verve Therapeutics Inc. (VERV) stock had its last reported insider trading activity 261 days ago on Dec 01. Bellinger Andrew, the CSO & CMO of the company, disposed of 865 shares for $22.95 on Dec 01. It resulted in a $19,852 divestment by the insider. Dorval Allison sold 554 shares at an average price of $22.10 on Nov 29. The insider now owns 2,186 shares following the transaction. On Nov 04, Member of 10% Group GV 2017 GP, L.L.C. sold 97,166 shares at $31.14 apiece. The transaction was valued at $3,025,611.
Valuation Metrics
The stock’s beta is 1.74. Besides these, the trailing price-to-sales (P/S) ratio of 263.78, the price-to-book (PB) ratio of 1.87.
Financial Health
In the three months ended June 30, Verve Therapeutics Inc.’s quick ratio stood at 14.30, while its current ratio was 14.30, showing that the company is able to pay off its debt. Based on annual data, VERV earned $167.63 million in gross profit and brought in $1.94 million in revenue.
A company’s management is another factor that investors consider when determining the profitability of an investment. In the past year, return on investment (ROI) was -30.10%. Return on equity (ROE) for the past 12 months was -37.10%.
According to the earnings report, the company had a higher net income in the recent quarter than it did in the previous quarter. VERV’s revenue rose 100.0% to $1.4 million during the quarter, while net income inched up to $2.09 million. While analysts expected Verve Therapeutics Inc. to report -$0.92 quarterly earnings, the actual figure was -$0.87 per share, beating the consensus estimate by 5.40%. During the quarter, the company generated -$60.94 million in EBITDA. The liabilities of Verve Therapeutics Inc. were 123.91 million at the end of its most recent quarter ended June 30, and its total debt was $77.86 million. The value of shareholders’ equity is $63.72 million.
Technical Picture
This quick technical analysis looks at Verve Therapeutics Inc.’s (VERV) price momentum. With a historical volatility rate of 66.98%, the RSI 9-day stood at 20.13% on 18 August.
With respect to its five-day moving average, the current Verve Therapeutics Inc. price is down by -21.91% percent or -$3.94. At present, VERV shares trade -32.56% below its 20-day simple moving average and -4.29% percent below its 100-day simple moving average. However, the stock is currently trading approximately -20.50% below its SMA50 and -62.76% below its SMA200.
Stochastic coefficient K was 0.87% and Stochastic coefficient D was 3.79%, while ATR was 1.09. Given the Stochastic reading of 0.32% for the 14-day period, the RSI (14) reading has been calculated as 26.76%. As of today, the MACD Oscillator reading stands at -1.85, while the 14-day reading stands at -2.62.
Analyst Ratings
Canaccord Genuity launched its rating on Verve Therapeutics Inc. (NASDAQ: VERV) to a Buy in a note to investors on April 13, 2023. Verve Therapeutics Inc. (VERV) has been rated Overweight by analysts. According to 1 brokerage firm, VERV is a sell, and 3 firms recommend it is a Hold. There are 0 analysts who say the stock is underweight. A total of 0 analysts rate Verve Therapeutics Inc. stock as buy, with 8 recommending it as overweight.
With a median target price of $35.00, the current consensus forecast for the stock is $13.00 – $75.00. Based on these forecasts, analysts predict Verve Therapeutics Inc. (VERV) will achieve an average price target of $41.73.
